Navigating market access: Launch strategies and health economic modelling for medical devices

Pharma Market Access Insights - from Petauri Evidence

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

29:22

The world often feels rigged. And this episode is a wake-up call to recognize the barriers that exist for those who don’t fit the traditional mold. In this episode, which is a kind of tribute to my dear departed Dad, I recount some powerful lessons from the man who was a brilliant psychiatrist and my biggest champion. He taught me that if something feels off about the environment you’re in, it probably is—and it’s absolutely hella-not your fault. We dare to break into the uncomfortable truth that many workplaces are designed for a very specific demographic, leaving neurodivergent individuals, particularly those on the autism spectrum, feeling excluded. I share three stories in which my Dad imparted to me more than my fair share of his wisdom, and I'm hoping you to can feel empowered. You'll learn that we can advocate for ourselves and others to create a more inclusive work culture. Newsletter Paste this into your browser if the newsletter link is broken - https://www.lbeehealth.com/ Join our Patreon - https://differentnotbrokenpodcast.com/patreon Mentioned in this episode: Sign Up For Our Newsletter Stay updated on all the things! Get added to our newsletter mailing list. Newsletter…

10 days ago 44:41

MP3•Episode home

Send us a text

Discover how health economics can support successful Medical Device launch, proposition development, and market access
This episode offers an insightful journey into the world of medical device market access. Specialists from our health economics and market access teams explore the hidden challenges faced by medical devices companies when taking new innovations to healthcare leaders, communicating value and demonstrating evidence, and offer tips on leveraging health economics for a successful launch.
Juliet Wallace (Senior Partnerships Coordinator) delves deep with our expert panel into the pivotal role of health economic evaluation in supporting market access for medical devices. Juliet puts audience questions to Hannah Palin (Director, Local Market Access), Calum Jones (Associate Director, Health Economics), and Evelyne Priestman (Consultant, Health Economics).
See full details at: https://mtechaccess.co.uk/launch-strategies-health-economic-modelling-medical-devices/

This episode was originally broadcast live as webinar in February 2025.
https://petauri.com/

Chapters

1. Introduction and meet the speakers (00:00:00)

2. Establishing a Clear Value Proposition (00:02:11)

3. Care Pathway Mapping and Modelling (00:07:24)

4. Importance of Early Health Economic Modelling (00:13:39)

5. Role of Pilots in MedTech (00:18:18)

6. Communicating Device Value to Stakeholders (00:27:35)

7. Health Economic Evaluations for Market Access (00:31:48)

8. Communicating Cost Effectiveness Evidence (00:38:51)

67 episodes

#Science #Fitness #Biology #Business #Medicine #Mtech Access #Pharmaceutical #Pharma #Market Access #Health Economics #Heores #Medtech #NHS #Healthcare

Pharma Market Access Insights - from Petauri Evidence

Navigating market access: Launch strategies and health economic modelling for medical devices

Pharma Market Access Insights - from Petauri Evidence

published 10 days ago

MP3•Episode home

Send us a text

This episode was originally broadcast live as webinar in February 2025.
https://petauri.com/

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Chapters

1. Introduction and meet the speakers (00:00:00)

2. Establishing a Clear Value Proposition (00:02:11)

3. Care Pathway Mapping and Modelling (00:07:24)

4. Importance of Early Health Economic Modelling (00:13:39)

5. Role of Pilots in MedTech (00:18:18)

6. Communicating Device Value to Stakeholders (00:27:35)

7. Health Economic Evaluations for Market Access (00:31:48)

8. Communicating Cost Effectiveness Evidence (00:38:51)

67 episodes

#Science #Fitness #Biology #Business #Medicine #Mtech Access #Pharmaceutical #Pharma #Market Access #Health Economics #Heores #Medtech #NHS #Healthcare

All episodes

Pharma Market Access Insights - from Petauri Evidence

1
Communicating value to US Payers: Insights for Pharma and Medtech 59:02

5 days ago59:02

59:02

Send us a text What do global market access teams need to know about the US market? What do US payers expect to hear from Pharma and Medtech companies? What kind of value messaging resonates in the US? How do you prepare for launch in a market as diverse as the US? In this Global Whispers episode, Louise Maddison (Senior Consultant – Global Market Access, Petauri Evidence) interviews some of our colleagues from Petauri Advisors who are either former payers, or former industry market access leads in the US. Louise puts your questions to: - Rory Davies – Vice President of Value and Access, Petauri Advisors, with extensive past experience in Chief Clinical roles at Cigna, Flipt and WellDyne - Dan Vanderpoel – Executive Vice President, Strategic Payer Marketing; Head, Client Solutions, Petauri and former Manager, Trade Relations at Humana - Shana Gunderson Hua – Vice President of Value and Access, Petauri Advisors and former Medical Affairs Executive Director at Genentech and former AVP of Pharmaceutical Strategy and Contracting at Cigna and Express Scripts (now Evernorth) We explore what global market access teams need to know about market access and payer engagement in the US. We explore how and why value messaging, pricing, and launch strategies are developed differently for the US market, compared to other key launch markets, and what this means for global teams preparing for US launch or taking a US-developed proposition internationally. Learn more at: https://petauri.com/insights/communicating-value-to-us-payers-insights-for-pharma-and-medtech/ This episode was first broadcast live as a webinar in March 2025. Learn more about Petauri Evidence: https://petauri.com/petauri-evidence/ Learn more about Petauri Advisors: https://petauri.com/petauri-advisors/ Meet the ACE team: https://petauri.com/about-us/ace-team/ Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence…

Pharma Market Access Insights - from Petauri Evidence

1
Navigating market access: Launch strategies and health economic modelling for medical devices 44:41

10 days ago44:41

44:41

Send us a text Discover how health economics can support successful Medical Device launch, proposition development, and market access This episode offers an insightful journey into the world of medical device market access. Specialists from our health economics and market access teams explore the hidden challenges faced by medical devices companies when taking new innovations to healthcare leaders, communicating value and demonstrating evidence, and offer tips on leveraging health economics for a successful launch. Juliet Wallace (Senior Partnerships Coordinator) delves deep with our expert panel into the pivotal role of health economic evaluation in supporting market access for medical devices. Juliet puts audience questions to Hannah Palin (Director, Local Market Access), Calum Jones (Associate Director, Health Economics), and Evelyne Priestman (Consultant, Health Economics). See full details at: https://mtechaccess.co.uk/launch-strategies-health-economic-modelling-medical-devices/ This episode was originally broadcast live as webinar in February 2025. https://petauri.com/ Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence…

Pharma Market Access Insights - from Petauri Evidence

1
Navigating US payer evidence needs to optimise market access 57:34

23 weeks ago57:34

57:34

Send us a text What clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of preferential access in the US with the right evidence? How should evidence be generated, synthesised, and presented for the US market? In this episode, Clare Foy (Director – Global Market Access, Mtech Access) interviews colleagues Nicole Lodowski (Managing Director, Petauri Evidence) and Bob Nordyke (Senior Advisor, Petauri Evidence) about US payer evidence challenges. We explore the evolving evidence needs for US payers. Nicole and Bob share unique perspectives around their extensive experience of driving evidence strategies for US pharmaceutical and medical device launches. Additionally, Nicole and Bob share a ‘sneak peek’ of exclusive insights from a recent Petauri US payer insights survey conducted to better understand the evidence landscape from the US payers’ perspective. They explore: The evolving payer evidence landscape in the US Preferences for clinical and economic evidence by US payers Key differences between the US and other global markets with regard to evidence, HEOR, and market access Opportunities and challenges when launching new medicines/medical devices/diagnostics in the US Innovative perspectives on evidence planning and strategy for the US market US payers’ perspectives, with exclusive insights from Petauri Evidence’s 2024 US payer survey This episode was first broadcast as a live webinar in October 2024. Learn more at: https://mtechaccess.co.uk/navigating-us-payer-evidence-needs/ Explore more about launching in the US market: https://mtechaccess.co.uk/launching-healthcare-products-in-the-us/ Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence…

Pharma Market Access Insights - from Petauri Evidence

1
Best practice RWE approaches to support economic modelling for HTA 59:53

24 weeks ago59:53

59:53

Send us a text How can real-world evidence (RWE) support health technology assessment (HTA)? Can real-world data (RWD) supplement clinical data? How can RWE be used to solve common challenges with treatment comparison? Here, Mtech Access are joined by experts from Arcturis and Delta Hat. Dan Howard (Associate Director – Health Economics, Mtech Access) shares some of the challenges that our clients face when developing HTA-ready health economic models with limited clinical trial data. Joseph O’Reilly (Principal Medical Statistician, Arcturis) introduces solutions to these challenges using RWD and RWE approaches. Nick Latimer (Analyst, Delta Hat; Professor of Health Economics, University of Sheffield; former NICE Appraisal Committee member) discusses how RWE is assessed by HTA committees. Samantha Gillard (Director – HTA, Mtech Access) facilitates the discussion and puts your questions to our experts This episode was first broadcast as a live webinar in October 2024. To request a copy of the slides used or to learn more visit: https://mtechaccess.co.uk/rwe-approaches-economic-modelling-hta/ For support with real-world evidence analysis, health economic modelling of health technology assessment, email info@mtechaccess.co.uk or visit https://mtechaccess.co.uk/ Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence…

Pharma Market Access Insights - from Petauri Evidence

1
NHS winter planning 2024–25 – Engaging with NHS decision-makers through Autumn to Christmas 1:02:50

24 weeks ago1:02:50

1:02:50

Send us a text How is the NHS preparing for winter? Which challenges are the most pressing for NHS decision-makers? How can industry best engage and support NHS decision-makers in the next few months? In August, Karen Cooper (Senior Consultant – NHS Insight & Interaction, Mtech Access) was joined by Jo Turl (Former Director of Commissioning, Devon ICS) to explore these challenges. Jo and Karen discuss: How ICBs and Directors of Commissioning prepare for winter pressures The current key areas of focus at Place and ICB level Specific challenges and pressures facing the NHS now and in the run up to winter Immediate and long-term impact of (expected) new government policies How industry can best support the NHS as it plans for winter and beyond How your field teams can engage with NHS commissioners over the next few months This episode was first broadcast as a live webinar in August 2024. Learn more at https://mtechaccess.co.uk/nhs-winter-planning/ For support with your UK market access and NHS engagement strategy, visit: https://mtechaccess.co.uk/strategic-uk-market-access/ or email info@mtechaccess.co.uk Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence…

Pharma Market Access Insights - from Petauri Evidence

1
De-mystifying the NHS – What you need to know about the NHS as a market for your health technology 56:15

29 weeks ago56:15

56:15

Send us a text Are you a global market access lead looking to understand the challenges faced by your UK affiliates? Or do you work at a national level with responsibility for bringing a new health technology to the NHS in England? In July 2024, Global Whispers and NHS Whispers came together, to bring you an overarching view of what it takes to access the NHS with a medtech or pharmaceutical innovation. Guest speaker Dr Faris Al-Ramadani who shared his experience of introducing new technologies to the NHS from both sides of the fence: as a PCN Clinical Director and GP Partner, and as a HealthTech and Venture Capital Consultant. The NHS in England is complex and ever changing. Recent years have seen the introduction of new structures, new decision-makers and new priorities. If you’ve fallen out of the loop of what’s happening with the NHS, this webinar is here to help. After de-ciphering some of the new(er) NHS terminologies and structures, we discuss: The key steps for introducing a new health technology to the NHS Who to speak to, when and where What to include in your value proposition to appeal to NHS decision-makers How to best meet key stakeholders’ needs The challenges of bringing a new technology to the NHS in England Learn more about this webinar at: https://mtechaccess.co.uk/de-mystifying-the-nhs/ Discover more about how we can support your UK launch strategy at: https://mtechaccess.co.uk/strategic-uk-market-access/ This webinar was first broadcast live as a webinar in July 2024 Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence…

Pharma Market Access Insights - from Petauri Evidence

1
NHS primary care panel – the GP Contract and Operational Planning Guidance 1:02:14

34 weeks ago1:02:14

1:02:14

Send us a text What can we expect to see in primary care in the NHS given recent policy announcements and ongoing uncertainty? What does the new GP Contract tell us about the future of primary care? What are the biggest challenges facing primary care in 2024–25? In this webinar, Karen Cooper (Senior Consultant – NHS Insight & Interaction, Mtech Access) spoke to a panel of NHS Associates about the current state and future of primary care and what this means for industry. Our panellists were: - Jack Wagstaff (Place Leader, Surrey Heartlands Health and Care Partnership, Chief Officer for North West Surrey Health and Care Alliance) - Zafran Azam (Head of Medicines Optimisation and Delivery, Derby City Place) - Dr Neil Forster (GP and PCN Clinical Director, Northumberland Medical Alliance) We explore: - Where NHS primary care is heading and what this means for your strategy and business planning - Prescribing and decision-making in primary care - The implications of the GP Contract for PCNs, GPs, patients, and industry - What this means for integration and the integrated care model - Policy priorities in practice and what to expect in an election year - How Pharma, Medtech, and Diagnostics companies can best engage with primary care leaders Learn more at: https://mtechaccess.co.uk/nhs-primary-care-gp-contract/ Discover more about our UK market access services at: https://mtechaccess.co.uk/uk-nhs-insights/ Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence…

Pharma Market Access Insights - from Petauri Evidence

1
Engage NHS healthcare decision-makers with RWD 20:55

38 weeks ago20:55

20:55

Send us a text Discover how data visualisation dashboards can aid field teams in market access discussions with customers. Healthcare leaders look to real-world data (RWD) to inform decisions. Field teams presenting decision-makers with RWD within a well-designed, easy-to-use visualisation can build a case for change, while positioning themselves as a trusted partner. Watch this 20-minute discussion between Iain Shield (Associate Director – Market Access) and Ben Spurr (Head of Partnerships) to discover how Connected Insights data visualisation dashboards can help your teams have strategic conversations with healthcare decision-makers. Iain also explains typical use cases for the dashboards for field teams, why data dashboards are useful for the NHS, and what sets Connected Insights dashboards apart. Learn more about this showcase at: https://mtechaccess.co.uk/engage-nhs-with-rwd/ Learn more about real-world data visualisation at: https://mtechaccess.co.uk/digital-capabilities/real-world-data-market-access/ Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence…

Pharma Market Access Insights - from Petauri Evidence

1
Market access and reimbursement in Canada – changes at CADTH 47:43

45 weeks ago47:43

47:43

Send us a text What do you need to know about the market access and reimbursement landscape in Canada? What changes can we expect at the Canadian Agency for Drugs and Technologies in Health (CADTH) in 2024/2025? In this webinar, Clare Foy (Director – Global Market Access, Mtech Access) interviewed Don Husereau (Adjunct Professor of Medicine, The University of Ottawa). We take a look at the market access, health policy, and health technology assessment in Canada. Clare Foy and Don Husereau explore: The market access landscape in Canada Upcoming changes at CADTH What Canadian payers expect from your value proposition Opportunities and challenges when launching new medicines/medical devices/diagnostics in Canada How Canada compares to the USA/key European launch markets What this means for your global market access strategy This episode was first broadcast as a live webinar in March 2024. Learn more at https://mtechaccess.co.uk/market-access-canada-changes-cadth/ Learn more about the Canadian healthcare market and launching new pharma and medtech innovations at: https://mtechaccess.co.uk/launching-healthcare-products-in-canada/ Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence…

Pharma Market Access Insights - from Petauri Evidence

1
Rare Disease market access in the MENA and Nordic regions 59:10

51 weeks ago59:10

59:10

Send us a text Where will you be launching your new orphan medicine? You may be confident that your Global market access strategy will support access in key launch markets like the UK, the EU4 and the US, but have you thought about other markets? Have you looked at the reimbursement requirements for rare disease products in the Nordic markets? Have you explored opportunities in growth markets, such as those in the Middle East and North Africa (MENA) region? In this webinar, our Global Market Access team compare and contrast access opportunities and challenges for rare disease treatments in the differing markets of the Nordic and MENA regions, asking: what does this mean for your overarching market access strategy? Our Global Market Access experts explore contrasting regions to showcase the significant differences between international markets when it comes to: - Overall and rare disease patient populations - Access inequalities - Time to diagnosis - Access to innovation timelines - Healthcare funding - Health technology assessment frameworks Robert Taaffe (Consultant – Global Market Access) presents his research into the market access conditions in the MENA regions, with a focus on the rare disease reimbursement landscape in growth markets in Egypt, Saudi Arabia, and the United Arab Emirates. Michelle James (Associate Consultant – Global Market Access) showcases market access and reimbursement routes in the more established, yet smaller populations in the Nordic regions. Michelle will focus on access in Denmark, Sweden, and Norway. Clare Foy (Director – Global Market Access) leads our discussion on the opportunities and challenges of launching in markets with different conditions and requirements, and how this should play into your overarching Global market access strategy. Learn more at and request a copy of the webinar slides at: https://mtechaccess.co.uk/rare-disease-market-access-nordic-and-mena/ Discover how Mtech Access can support you with market access, pricing and reimbursement for rare disease treatments at: https://mtechaccess.co.uk/global-market-access-and-pricing/ Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence…

Pharma Market Access Insights - from Petauri Evidence

1
How does funding flow in NHSE Regions? 1:00:15

1 year ago1:00:15

1:00:15

Send us a text Which decisions are made at Region level in the NHS in England? How do finances and funding work at this level? And how can industry best support and engage with Region leaders? We sit down with guest speaker Richard Smale (Interim Director of System Co-ordination, NHS England [NHSE] – South West) for an all-encompassing discussion that explored finance, funding flows, system priorities, and the decision-making process in NHS Regions. Richard heads up system co-ordination work across the NHS South West Region. The Region has seven Integrated Care Boards (ICBs), 22 Trusts, nine counties and a resident population of over 5.5 million patients stretching from Gloucestershire and Wiltshire to the Isles of Scilly. The interview was led by David Thorne (Principal Consultant, Mtech Access and Transformation Director at Well Up North Primary Care Network [PCN]) who put both the NHS and industry perspectives to Richard to explore the real state of the NHS. In this episode, David and Richard discuss: - Where the NHS is heading and what this means for your strategy and business planning - Decision making, finances, and funding flows across the NHS - The role of NHS Regions, particularly with key funding decisions like Specialised Commissioning - Delivering service change across integrated systems - Policy priorities in practice and what to expect in an election year - How Pharma, Medtech, and Diagnostics companies can best engage NHS leaders at Region level This episode was first broadcast as a live webinar in February 2024. Learn more about the webinar and Richard at: https://mtechaccess.co.uk/how-does-funding-flow-in-nhse-regions/ Discover more about our NHS Insights services at: https://mtechaccess.co.uk/uk-nhs-insights/ Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence…

Pharma Market Access Insights - from Petauri Evidence

1
NHS policy for 2024/25: strategy and engagement in a world of uncertainty (recorded in Jan 2024) 1:02:06

1 year ago1:02:06

1:02:06

Send us a text What do we know about plans and policy for 2024/25? As the expected central operating plan had not materialised (at time of recording), and with a general election and a potential Labour government on the horizon, how can NHS and industry drive forward improvements and innovation? Host Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) was joined by guest speakers Debbie Morgan (Director of Service Improvement and Transformation, Cambridge University Hospitals NHS Foundation Trust), Ellen Rule (Deputy CEO/Director of Strategy & Transformation, Gloucestershire Integrated Care Board) and Dr Viren Mehta (GP Partner, GP Federation Chief Officer, Viaduct Care). Together we explored what all this uncertainty means for NHS decision-making, day-to-day operations, strategy, and engagement with industry. In this webinar, we bring together leaders from across the NHS to explore how they are planning and operating in this uncertainty. We explore: - Strategy and planning in these times of uncertainty - What’s happening with GP contracts - Financial pressures and challenges - If/where it’s possible to drive forward change in the current environment - How Pharma and Medtech can best support NHS leaders - Where the panel would welcome solutions from industry Please note this episode was first broadcast in January 2024 as a live webinar. Some aspects of policy discussed have evolved and continue to evolve. Discover more at: https://mtechaccess.co.uk/nhs-policy-for-2024-25/ Learn more about our NHS insights services at: https://mtechaccess.co.uk/uk-nhs-insights/ Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence…

Pharma Market Access Insights - from Petauri Evidence

1
De-mystifying health economic model classifications and structures 1:00:28

1 year ago1:00:28

1:00:28

Send us a text What is health economic evaluation and which modelling approaches can be used to support market access activities? In this episode, our expert health economists explain the key strengths and limitations of the most common health economic modelling classifications and structures. Here, Hannah Gillies (Consultant – Health Economics) and Daniel MacDonald (Associate Consultant – Health Economics) de-mystify the different approaches to health economic modelling. Our specialists explore six of the most common health economic modelling structures used to support market access activities; - Decision trees - Markov models - Semi-Markov models - Partitioned survival models - Cox regression models - Discrete event simulations This episode was first broadcast as a live webinar in January 2024. For more information or to request a copy of the slides used, please visit: https://mtechaccess.co.uk/de-mystifying-health-economic-models/ Work with our health economists: https://mtechaccess.co.uk/health-economics/ Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence…

Pharma Market Access Insights - from Petauri Evidence

1
Evidence strategy for Medical Technologies and Diagnostics 53:24

1 year ago53:24

53:24

Send us a text Here, our experts explore evidence strategies for medical devices, diagnostics and digital health technologies. Have you established the clinical and economic value of your medical device, diagnostic or digital technology? Do you have the evidence required to support your value proposition? Would a health technology assessment (HTA) route be appropriate for your product? What will payers, HTA agencies, and other key decision makers be looking for? And how should this information be presented? In this episode, our experts in HTA, health economics, and commercialisation explore: - How to identify and communicate the value of your product for patients and the wider healthcare system - How to build a robust evidence package for successful launch and commercialisation - Key requirements for the National Institute for Health and Care Excellence (NICE) Medical Technologies Evaluation Programme (MTEP) or Diagnostics Assessment Programme (DAP) - Next steps to take your innovation to healthcare leaders across the NHS and beyond, with an impactful customer communication strategy This episode was first broadcast as a live webinar in January 2023. Learn more and request a copy of the slides at: https://mtechaccess.co.uk/evidence-strategy-for-medical-technologies-and-diagnostics/ Discover how Mtech Access can support your commercialisation journey at: https://mtechaccess.co.uk/medical-device-market-access/ Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence…

Pharma Market Access Insights - from Petauri Evidence

1
How to set your Pharma or Medtech product up for success in the US market 43:06

1 year ago43:06